Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis

Wang, Leiming; Yang, Xi; Zhou, Fei; Sun, Xuesi; Li, Shulin

doi:10.1080/21655979.2022.2036894

Cited by 29 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was noted that ASF1B activated PI3K/AKT/mTOR signaling to facilitate CDDP resistance of TNBC cells. These findings showed the functional role of circUBAP2/miR-300/ASF1B/PI3K/AKT/ mTOR (PAM) pathway in CDDP-resistant TNBC [89]. In another study, the overexpression of Cerebellar degenerationrelated protein 1 (CDR1) was reported to be associated with adverse chemotherapeutic effects, and the sensitivity of the drug-resistant breast cancer cells to cisplatin was increased through the involvement of competitive inhibition of miR-7 and REGγ [90].…”

Section: Cisplatinmentioning

confidence: 99%

circRNAs in drug resistance of breast cancer

Mısır¹,

YAMAN²,

PETROVIĆ³

et al. 2022

Oncology Research

View full text Add to dashboard Cite

Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment.Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends.Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicininduced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance.

show abstract

Section: Cisplatinmentioning

confidence: 99%

circRNAs in drug resistance of breast cancer

Mısır¹,

YAMAN²,

PETROVIĆ³

et al. 2022

Oncology Research

View full text Add to dashboard Cite

show abstract

“… 42 Hsa_circ_0000199 and circUBAP2 not only have pro‐cancer effects on triple‐negative breast cancer (TNBC) but also promote the resistance of cisplatin (DDP) by activating the PI3K/Akt/mTOR pathway. 94 , 95 CircWHSC1 upregulation not only plays a role in EC but also accelerates malignant cell phenotype of cells in BC. 96 The molecular mechanism is CircWHSC1 regulates the fatty acid synthase (FASN)/AMPK/mTOR Axis through sponging miR‐195‐5p in BC.…”

Section: Other Cancersmentioning

confidence: 99%

“…According to GLOBOCAN's 2020 Global Cancer Statistics, breast cancer (BC) has surpassed lung cancer to become the most common cancer 42 . Hsa_circ_0000199 and circUBAP2 not only have pro‐cancer effects on triple‐negative breast cancer (TNBC) but also promote the resistance of cisplatin (DDP) by activating the PI3K/Akt/mTOR pathway 94,95 . CircWHSC1 upregulation not only plays a role in EC but also accelerates malignant cell phenotype of cells in BC 96 .…”

Section: Other Cancersmentioning

confidence: 99%

The roles and mechanisms of circular RNAs related to mTOR in cancers

Cao

Wang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Circular RNAs (circRNAs) are stable molecules with covalently closed structures that have an irreplaceable role in the occurrence, progression, and even treatment of plenty of cancers. Mammalian/mechanistic target of rapamycin (mTOR) is a key regulator in cancers and plays several biological functions, such as proliferation, migration, invasion, autophagy, and apoptosis. Methods All data were collected through PubMed and CNKI, using terms including “circRNA,” “mTOR,” “caner,” “signaling pathway,” “biomarker,” “diagnosis,” “treatment.” Articles published in Chinese and English were included. Results In this review, the expression, function, and mechanism of circRNA‐associated mTOR in cancers were described. CircRNA‐associated‐mTOR can regulate the progression and therapy of a variety of cancers in multiple signaling pathways, such as phosphatidylinositol‐3‐kinase (PI3K)/protein kinase B (Akt)/mTOR, mitogen‐activated protein kinase (MAPK)/mTOR, and AMP‐activated protein kinase (AMPK)/mTOR axis. These cancers including esophageal carcinoma (circLPAR3, ciRS‐7), gastric cancer (circNRIP1, hsa_circ_0010882, hsa_circ_0000117, hsa_circ_0072309, and circST3GAL6), colorectal cancer (hsa_circ_0000392, hsa_circ_0084927, hsa_circ_0104631, and circFBXW7), liver cancer (circC16orf62, hsa_circ_100338, hsa_circ_0004001, hsa_circ_0004123, hsa_circ_0075792, hsa_circ_0079299, and hsa_circ_0002130), pancreatic cancer (circ‐IARS and circRHOBTB3), renal carcinoma (ciRS‐7), bladder cancer (circUBE2K), prostate cancer (circMBOAT2 and circ‐ITCH), ovarian cancer (circEEF2, circRAB11FIP1, circMYLK, and circTPCN), endometrial cancer (hsa_circ_0002577 and circWHSC1), lung cancer (circHIPK3, hsa_circ_0001666), thyroid cancer (hsa_circ_0007694 and hsa_circ_0008274), glioma (circGFRA1, circ‐MAPK4, circPCMTD1, and hsa_circ_0037251), osteosarcoma (circTCF25), leukemia (circ‐PRKDC), and breast cancer (hsa_circ_0000199, circUBAP2, and circWHSC1).

show abstract

“…Recently, over-expression of circSMARCA5 has been verified to increase the chemosensitivity of BC cells to cisplatin through interacting with host gene SMARCA5 and inhibiting DNA damage repair [71]. More recently, CircUBAP2 has been verified to induce the cisplatin resistance of TNBC via microRNA-300/anti-silencing function 1B histone chaperone axis, which further triggered the PAM signaling [72].…”

Section: The Dysregulation Of Circrnas Is Related To Drug Resistance ...mentioning

confidence: 99%

Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer

Guo¹,

Hua²

2022

neo

View full text Add to dashboard Cite

Systematic treatments including chemotherapy, endocrine therapy, and HER2-targeted therapy are important therapeutic approaches to breast cancer. However, drug resistance is a major barrier to achieving cure in breast cancer (BC) patients. Hence, it is urgent to gain insight into the drug-resistance mechanisms in order to improve the prognosis of BC patients. Genetic alternations, epigenetic alternations, and other non-genetic mechanisms such as BC stem-like cells, metabolic reprogramming, and tumor microenvironment contribute to drug resistance of BC. With the development of single-cell sequencing of circulating tumor cell and next-generation sequencing of matched pre-and post-progression tumor biopsies or ctDNA from BC patients with drug resistance, new mechanisms of resistance are being discovered. An increasing number of microRNAs and long non-coding RNAs have been found to be associated with the drug resistance of BC. However, there are few reports on the role of circular RNAs (circRNAs) as master regulators of drug resistance.Therefore, there is still much to say in the field of drug resistance-related circRNAs. In this review, we mainly focus on literature evidence for the detailed mechanisms associated with systematic expression of tumor suppressive circRNAs or knockdown of oncogenic circRNAs has been verified to reverse drug resistance of BC cells, which highlights that circRNAs may function as potential biomarkers and/or therapeutic targets of BC. Treatment targeting abnormally expressed circRNAs alone or combined with other systemic treatments may be a promising approach to conquering drug resistance.

show abstract

Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis

Cited by 29 publications

References 50 publications

circRNAs in drug resistance of breast cancer

circRNAs in drug resistance of breast cancer

The roles and mechanisms of circular RNAs related to mTOR in cancers

Circular RNAs: novel regulators of resistance to systemic treatments in breast cancer

Contact Info

Product

Resources

About